Research programme: tryptase inhibitors - ProthericsAlternative Names: Tryptase inhibitors research programme - Protherics
Latest Information Update: 16 Jul 2002
At a glance
- Originator Protherics
- Mechanism of Action Tryptase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 16 Jul 2002 Discontinued - Preclinical for Asthma in United Kingdom (unspecified route)
- 10 Mar 2000 Protherics is seeking a development partner for its tryptase inhibitors (http://www.protherics.com/)
- 21 Oct 1999 Proteus International has merged with Therapeutic Antibodies to form Protherics